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INTRODUCTION:  The  occurrence  of  multiple  primary  tumors  is rare.  Only  limited  number  of  cases  with
triple  malignancy  have  been  reported.  We  report  here  a rare  case  of a  woman  presented  synchronous
triple  tumors,  in her lung,  breast,  skin.
PRESENTATION OF  CASE:  A 56-year-old  woman  presented  with  invasive  ductal  carcinoma  of breast,  non-eywords:
elanoma
reast cancer
on  small cell lung cancer
small  cell  lung  cancer  and  malignant  melanoma.  The  patient  undergone  mastectomy  and  malignant
melanoma  tumor  excision  on-site.  After operation  stereotactic  radiotherapy  was  given  to  her  lung  tumor.
Six  course  of chemotherapy  was  given  to her.  She  is alive  with  no  progression.
DISCUSSION: The  patient  was  diagnosed  with  melanoma  and  staging  by FDG/PET.  There  is  not  any  study
about  routine  using  PET/CT  in  the melanoma  staging.
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. Introduction
Synchronous multiple primary tumors are rare.1–7 Most syn-
hronous triple tumors have been reported by Japanese authors.8
ost of synchronous multiple primary tumors are seen in geni-
ourinary system and gastrointestinal system.5–7
Herein, we  report an extremely rare case of synchronous triple
rimary cancers of breast, lung (non-small cell lung cancer) and
alignant melanoma..  Presentation of case
A 56-year-old postmenopausal female with complaints of
apidly growing hyperpigmented mass in left leg noticed 6 months
go sought medical consultant in November 2011. On examination
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a colorful mole with an irregular borders in the 1/3 upper lateral
side of left leg was found. Excisional biopsy of lesion showed malig-
nant melanoma. Pathology revealed that lesion thickness 2.8 mm,
Clark Level IV, epitheloid cell type, with ulceration, low mitotic rate,
superﬁcial spreading type.
An  18F-FDG PET/CT was ordered for initial staging and workup
to evaluate metastatic spread of disease. The 18F-FDG PET/CT
demonstrated the following: intense FDG uptake within the left
breast mass on the lower inner quadrant (size 1.2 cm × 1.1 cm,
SUVmax: 7.3); abnormal lymph node uptake in the left pelvis region
(SUVmax: 10); abnormal uptake on the lower lobe of right lung
(size 1.3 cm × 1.1 cm,  SUVmax: 6.5), elevated nodular activity in
the left adrenal gland (SUVmax: 6) (Fig. 1). MRI  of adrenal gland
ruled out any metastasis. Subsequent mammography and ultra-
sonograpy of the left breast revealed a hyperdense 1.2 cm × 1.2 cm
mass within the 2 o’clock position, with ill-deﬁned and angulated
borders, assessed as a BIRADS category 5. There was  a second
lesion within the 11 o’clock position of the same breast, measuring
0.9 cm × 0.6 cm and 0.5 cm × 0.4 cm also considered suspicious for
malignancy, assessed as a BIRADS category 4.
Trans thoracic FNAB (ﬁne needle aspiration biopsy) of lung
lesion revealed squamous cell carcinoma (Figs. 2 and 3). Given the
PET-CT, chest tomography and biopsy results, this patient was  diag-
Open access under CC BY-NC-ND license. nosed with Stage 1a non-small cell lung cancer (T1N0M0 NSCLC).
The patient received a hypo-fractionated course of Stereotactic
body radiotherapy (SBRT). A 3D-conformal multiﬁeld technique
was used with six coplanar and one non-coplanar statics beams.
A total dose of 60 Gy in three fractions over six days was  prescribed
to the 95% of the CTV.
 Ltd. Open access under CC BY-NC-ND license. 
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An ultrasound-guided core biopsy was performed of the larger
reast mass, revealed an invasive ductal carcinoma of breast with
egative melanoma markers. The patient underwent a subcuta-
eous nipple sparing mastectomy and reconstruction with the
reast prosthesis and the sentinel lymph node dissection for the
reast tumor and pelvic lymph node dissection for pelvic lymph
odes. Breast tumor and pelvic lymph nodes are successfully
reated using a one-stage surgical approach.Pathology of the breast surgery revealed a 1.5 cm poorly
ifferentiated inﬁltrating ductal carcinoma with an extensive
ntraductal component. There was no any other tumor. The mar-
ins were clear. The one sentinel node identiﬁed was free of
Fig. 2. Transthoracical ﬁne ne/CT.
tumor on pathological examination. Lymphovascular invasion
was not identiﬁed and necrosis was  not observed in the spec-
imen. The estrogen receptors and progesterone receptors (ER
and PR), c-erb B2 status were positive and the concentration of
ER was 95%, PR was 90%, c-erb B2 was  (+++) of the specimen
(Fig. 4).
Histologically, 10 lymph nodes were removed during lower
abdominal lymph node dissection and in one of them, metastasis of
breast cancer was found with extracapsular extension (T1N0M1).
Six cycles of cyclophosphamide, epirubicin and 5-ﬂurouracil
based chemotherapy and trastzumab, anastrozole were given to
the patient.
edle aspiration biopsy.
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Fig. 3. Lung FNAB. Upper left: Tumor sheets composed of atypical cells with large nuclei. They have conspicuous nucleoli and amphophilic cytoplasms. Upper right: Tumor
cells  have no immunohistochemical reaction with Melan-A stain. Lower left: Tumor cells have strong nuclear staining with TTF-1.
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Eighteen months after the diagnosis, the patient is alive and
ecurrence free.
. Discussion
Multiple synchronous primary carcinomas are known to occur
n many organ systems. The incidence of multiple primary can-
ers is reported about 0.73–11.7%.3 Cases of synchronous primary
umors have been well documented in the lung, genitourinary, hep-
tobiliary/gastrointestinal, and other systems.1–4
Incidence of multiple primary malignant neoplasms increases
ith age. A family history of cancer and genetic predisposition may
e associated with a risk of multiple malignancies.4 Some studies
howed the constitutional chromosomal abnormality as one of the
ossible high-risk factors for multiple primary cancers. A few stud-
es provides support for the hypothesis that decreased DNA repair
apacity is a contributory factor for multiple primary tumor.
The histological criteria are as follows: (1) Tumors must be
learly malignant as determined by histologic evaluation. (2) Each
eoplasm must be topographically separate and distinct. (3) The groups. Right: ER positivity in the tumor cells with metastatic carcinoma.
tumors should be separated by normal-appearing mucosa.1,4 We
conﬁrmed all tumors histologically.
Synchronous carcinomas are those tumors diagnosed at the
same time or within a 6-month period after the diagnosis of the
initial cancer.4
Recently improved tumor control with relatively few com-
plications has been achieved using high-dose, hypofractionated
stereotactic radiation delivery.5 We  treated the lung tumor of this
patient with SRS, successfully.
Adding PET/CT as a diagnostic tool improved the staging of stage
III patients with increased cost.6 There are a lot of studies in the lit-
erature showed that PET/CT have not any role in the initial staging
of melanomas with intermediate and thin thickness.7,8 There are
some studies showed that PET/CT has high speciﬁcity and sensi-
tivity identifying regional metastases in the melanomas with thick
thickness.9,10 However there is no study supporting the routine use
of PET/CT for patients undergoing SLNB for melanoma.11 Retrospec-
tive studies showed that PET/CT has changed therapeutic plan in the
patients with stage 3–4 melanoma between 22% and 49%.12,13 The
rates in the prospective trials are between 15% and 40%.14 PET/CT
ﬁndings may  contribute important information that led to the
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odiﬁcation of the original treatment plan in the melanomas
ith high mitotic rate, ulceration, lymphovascular invasion and
hick more than 2 mm.15 Our patient has 2, 8 mm thickness and
lcerative melanoma and her PET/CT ﬁndings changed therapy
lanning.
Recently studies suggest that mutations in the BRCA1 gene
ith breast-ovary cancer patients have increased risk of devel-
ping malignant melanoma by as much as 2.6 times.16 There are
ome reports showing synchronous tumors with breast cancer and
elanoma in the literature.17 However we could not observe any
ancer case of breast, lung and melanoma together in our clinical
ractice before.
. Conclusion
This case report that identiﬁes synchronously of breast cancer,
ung cancer and melonamin which is observed rarely is noteworthy.
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